We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET Helps Quantify Cancer Immunotherapy Target Engagement

By MedImaging International staff writers
Posted on 10 Apr 2019
Print article
Image: Radiolabeled WL12 lights up tumor in a mouse under a PET scan (Photo courtesy of Sridhar Nimmagadda / JHU-SOM).
Image: Radiolabeled WL12 lights up tumor in a mouse under a PET scan (Photo courtesy of Sridhar Nimmagadda / JHU-SOM).
A new study suggests positron emission tomography (PET) scans can be used to calculate engagement and tumor-residence kinetics of antibody therapeutics.

Researchers at Johns Hopkins University School of Medicine (JHU-SOM; Baltimore, MD, USA), Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), and other institutions developed a radiolabeled peptide that binds to programmed death ligand-1 (PD-L1), in order to study the mechanism of interaction between the checkpoint protein and the antibody therapeutics atezolizumab, avelumab, and durvalumab; how they are expressed in different tumors; and how efficiently and quickly they bind to PD-L1 receptors at the tumor using PET imaging.

The researchers found that both PD-L1–targeted monoclonal antibody drugs, and a high-affinity PD-L1–binding peptide called WL12 have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 and PET imaging demonstrated that variable PD-L1 expression and its saturation by antibody therapeutics can be quantified. Next, they used the radiotracer to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1; using mathematical modeling, they calculated the antibody therapeutic doses needed to achieve therapeutically effective occupancy (defined as over 90%). The study was published in the February 2019 issue of the Journal of Clinical Investigation.

“This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person, and give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly,” said senior author professor of radiology Sridhar Nimmagadda, PhD, of JHU-SOM. “Its use could streamline cancer therapy by enhancing doctors' ability to tailor therapy, help determine the therapeutic dose of a drug, and avoid or stop treatments that are not effective.”

Checkpoint inhibitors are designed to help the immune system recognize cancer cells as dangerous and target them for destruction. Tumors often hijack these natural protective systems, thus allowing them to masquerade as healthy tissues. PD-L1 is one such checkpoint target, and it is currently the backbone of immune checkpoint therapies.

Related Links:
Johns Hopkins University School of Medicine
Memorial Sloan-Kettering Cancer Center

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Oncology Information System
RayCare
Imaging Table
Stille imagiQ2
Mammography System
MAMMOVISTA B.smart

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.